<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TOPOTECAN HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(toe-po-tee'can)<br/><span class="topboxtradename">Hycamtin<br/></span><b>Classifications:</b> <span class="classification">antineoplastic, camptothecin agent</span>; <span class="classification">topoisomerase i inhibitor</span><br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>4 mg vials</p>
<h1><a name="action">Actions</a></h1>
<p>Antitumor mechanism is related to inhibition of activity of topoisomerase I, an enzyme required for DNA replication. Topoisomerase
         I is essential for the relaxation of supercoiled double-stranded DNA, which enables replication and transcription to proceed.
         Topotecan binds to the DNA-topoisomerase I complex.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Permits uncoiling but prevents recoiling of the two strands of DNA, resulting in a permanent break in the DNA strands.</p>
<h1><a name="uses">Uses</a></h1>
<p>Metastatic ovarian cancer, small cell lung cancer.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Previous hypersensitivity to topotecan, irinotecan, or other camptothecin analogs; acute infection; pregnancy (category D),
         lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Myelosuppression; history of bleeding disorders; previous cytotoxic or radiation therapy.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Metastatic Ovarian Cancer and Small Cell Lung Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 1.5 mg/m<sup>2</sup> daily for 5 d starting on day 1 of a 21 d course. Four courses of therapy recommended. Subsequent doses  can be adjusted by 0.25 mg/m<sup>2</sup> depending on toxicity<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Initiate therapy only if baseline neutrophil count <img src="../images/special/greaterorequal.gif"/>1500/mm<sup>3</sup> and platelet count <img src="../images/special/greaterorequal.gif"/>100,000/mm<sup>3</sup>. Do not give subsequent doses until neutrophils &gt;1000/mm<sup>3</sup>, platelets <img src="../images/special/greaterorequal.gif"/>100,000/mm<sup>3</sup>, and Hgb = 9.0 mg/dL.
                  </li>
<li> 					Note: Dosage adjustments to 0.75 mg/m<sup>2</sup> are recommended with moderate renal impairment. 				
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Reconstitute each 4-mg vial with 4 mL sterile water for injection to yield 1 mg/mL. Withdraw the required dose and inject
                  into 50100 mL of NS or D5W. If skin contacts drug during preparation, wash immediately with soap and water.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Give over 30 min immediately after preparation.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store vials at 20°25° C (68°77° F); protect from light. Reconstituted vials are stable for
            24 h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> <span class="speceff-common">Asthenia, fever, fatigue</span>. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting, diarrhea, constipation, abdominal pain, stomatitis, anorexia,</span> transient elevations in liver function tests. <span class="typehead">Hematologic:</span> <span class="speceff-both">Leukopenia, neutropenia</span> <i>,</i> <span class="speceff-common">anemia, thrombocytopenia</span>. <span class="typehead">Respiratory:</span> <span class="speceff-common">Dyspnea</span>. <span class="typehead">Skin:</span> <span class="speceff-common">Alopecia.</span>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> Increased risk of bleeding with <span class="classification">anticoagulants</span>, <span class="classification">nsaid</span>s, <span class="classification">salicylates</span>, <span class="classification">antiplatelet agents</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> 35% bound to plasma proteins. <span class="typehead">Metabolism:</span> Undergoes pH-dependent hydrolysis. <span class="typehead">Elimination:</span> Approximately 30% excreted in urine. <span class="typehead">Half-Life:</span> 23 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain CBC counts with differential frequently; periodically monitor ALT.</li>
<li>Assess for GI distress, respiratory distress, neurosensory symptoms, and S&amp;S of infection throughout therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn common adverse effects and measures to control or minimize when possible. Immediately report any distressing adverse
            effects to physician.
         </li>
<li>Avoid pregnancy during therapy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>